In February 2023, Seegene met with Marta del Pino at Eurogin, the leading international conference focused on human papillomavirus (HPV) and associated cancers, to discuss the value of HPV testing and genotyping in the new cervical cancer screening paradigm.
The noninvasive test evaluates eight 3D genomic markers and is the only test that returns a binary result to the ordering physician with high accuracy: “low probability” or “high probability” of response to an ICI.
The Nu.Q NETs test is the first approved clinical assay to assess disease severity by quantifying circulating nucleosomes which make up plasma neutrophil extracellular traps, or NETs — snares of DNA expelled by neutrophils to trap and kill invading pathogens.
Seegene has joined hands with LabHouse, a testing center in Vietnam, to launch the In-Life PCR campaign for ride-hailing drivers in Ho Chi Minh and Hanoi, and the company is in talks with testing labs in countries around the world to launch the campaign in more regions,
Diagnostic laboratories in the EU can utilize the IVDR-compliant PAXgene Blood ccfDNA workflow in a variety of noninvasive ccfDNA-based diagnostic applications.
Recent recommendations from the ESMO Precision Medicine Working Group and National Comprehensive Cancer Network, coupled with US Food and Drug Administration review and approval, have highlighted the use of tumor mutational burden testing in clinical practice for a number of different tumor types.